The use of PD-1/PD-L1 immune check point inhibitor is generally well tolerated and publications of prospective phase 2 studies [19, 20] on cemiplimab have shown impressive response of patients with recurrent advanced/metastatic cSCC being sensitive to PD-1 blockade. Here, CD274 is linked to skin squamous cell carcinoma.